Vepdegestrant (ARV-471)
ER+/HER2- Advanced Breast Cancer
Phase 3Active - Pivotal VERITAC-2 trial met primary endpoint
Key Facts
Indication
ER+/HER2- Advanced Breast Cancer
Phase
Phase 3
Status
Active - Pivotal VERITAC-2 trial met primary endpoint
Company
About Arvinas
Arvinas is a leader in the field of targeted protein degradation, founded on groundbreaking research from Yale University. The company's PROTAC® platform enables the development of therapeutics that harness the body's natural protein disposal system to degrade disease-causing proteins, potentially addressing previously 'undruggable' targets. With multiple clinical-stage assets, strategic partnerships, and a robust discovery engine, Arvinas aims to revolutionize treatment for serious diseases in oncology and neurology.
View full company profile